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Atherosclerosisa b s t r a c t
As a cleavage enzyme of precursor TNF-a, the high expression level of ADAM17 in endothelial cells is
an important factor in atherosclerosis. In this study, we demonstrate that ADAM17 is the target of
miR-152. We found that miR-152 could reduce TNF precursor cleavage and inhibit cell proliferation
and migration by targeting ADAM17 in human umbilical vein endothelial cells (HUVECs).
Furthermore, the expression pattern of miR-152 and corresponding target ADAM17 was opposite
in HUVECs under hypoxic conditions. The levels of circulating miR-152 in AS patient sera were lower
than those detected in the sera of normal individuals. Our results indicate that miR-152 may be
involved in the development of human atherosclerosis and could be used as diagnostic biomarker
or therapeutic target in atherosclerosis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis (AS) is a common chronic disease contributing
to high mortality and morbidity all over the world. As a disease
of polygenetic inheritance, AS shows signiﬁcant genetic heteroge-
neity, and the incidence presents regionalist and ethnic speciﬁcity.
The course of atherosclerosis is regulated by multiple levels of
response mechanisms and the etiology is highly complex [1].
Research has shown that inﬂammation, endothelial cell dysfunc-
tion and abnormal lipid metabolism are critically involved in the
pathogenesis [2].
The disintegrin–metalloproteinases (ADAMs) family is a group
of recently identiﬁed cell-surface glycoproteins. Members of the
ADAMs family (ADAM 8, 9, 10, 12, 15, 17, 19 and 28) are expressed
widely in epithelial cells, smooth muscle cells and leukocytes [3,4].
As a well-known ectodomain sheddase, ADAM17 plays an
important role in vascular physiological and pathological processes
through regulating membrane-anchored protein maturation [5].
Recent studies have shown that patients with myocardialinfarction have increased expression of ADAM17 in plaques [6]
and microparticles of human atherosclerotic plaques contain
active ADAM17 that is capable of cleaving inﬂammatory factors
from endothelial cells [7]. These inﬂammatory factors, including
transforming growth factor-b (TGF-b), platelet derived growth fac-
tor (PDGF), basic ﬁbroblast growth factor (bFGF) and vascular cell
adhesionmolecule (VCAM)may lead to proliferation and migration
of vascular smooth muscle cells, intimal hyperplasia and induction
of mononuclear and macrophage inﬂammatory inﬁltration or
conversion into foam cells. This complex process ultimately results
in atherosclerotic plaque formation and luminal stenosis [8–10].
MicroRNAs are a class of evolutionarily conserved non-coding
RNAs consisting of 19–22 nucleotides which play a pivotal role in
the initiation and progression of vascular disorders by modulating
the expression of molecules involved in vascular tone, inﬂamma-
tion and remodeling, thus inducing endothelial dysfunction
[11,12]. It also has been shown that microRNAs involved in the
regulation of members of the ADAMs family [13–16].
Circulating microRNAs are present in circulating blood, which
function as negative regulators of gene expression. It has been
reported that vascular endothelial cells produce circulating
microRNAs, such as miR-126 and miR-143/145 and that mediate
autoregulation or regulate the function of other cells [17,18]. These
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are involved in the development of vascular diseases such as AS.
In this study, we demonstrated for the ﬁrst time that miR-152
reduced TNF precursor cleavage and inhibited the proliferation
and migration of human umbilical vein endothelial cells (HUVEC)
by targeting ADAM17. The expression pattern of miR-152 and
corresponding target ADAM17 showed a negative correlation in
HUVEC in hypoxia or normoxia. We also found that the levels of
circulating miR-152 in AS patient sera were much lower than those
detected the sera of normal individuals. Our results indicated that
miR-152 may be involved in the development of human
atherosclerosis.
2. Materials and methods
2.1. Serum specimens and cell culture
Serum samples obtained from normal individuals and athero-
sclerosis patients (n = 10 per group) were acquired from General
Hospital of Chinese People’s Liberation Army (Beijing, China). All
patients had hyperlipidemia and were diagnosed with coronary
artery disease by coronary angiography and serum lipid tests.
The appearance of atherosclerotic plaques was conﬁrmed in all
patients by ultrasound examination of the carotid artery. Coronary
angiography showed varying degrees of stenosis in coronary artery
branches, including left anterior descending, circumﬂex, or right
coronary artery branch. All patients had unstable angina and or
myocardial infarction and were prepared to undergo coronary
artery bypass grafting. Serum samples were collected preopera-
tively. All of the serum specimens were obtained after consent
was given by patients.
Human umbilical vein endothelial cell lines (HUVEC, ATCC#
CRL-1730) were cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS,
Hyclone). The cells were maintained in a humidiﬁed incubator at
37 C with 5% CO2.2.2. DNA and RNA transfection
MiR-152 mimics were obtained from RiboBio (Guangzhou,
China): 50-TCAGTGCATGACAGAACTTGG-30; and miR-152 inhibitors
were obtained fromGenePharmaCompany (Shanghai, China): 50-CC
AAGUUCUGUCAUGCACUGA-30. ADAM17 siRNA were synthesized
by GenePharma (Shanghai, China): sense 50-CCAUGAAGAACACGUG
UAATT-30, antisense 50-UUACACGUGUUCUUCAUGGTT-30. Random
scrambled RNA from GenePharma was used as negative controls
(NC).
The pGL-3-control vector and the pRL-TK vector were kindly
provided by Dr. Zheng Xiaofei (Beijing Institute of Radiation
Medicine, China). Plasmids pCMV-myc and plasmids pCMV-
ADAM17-myc were purchased from OriGene Company (OriGene,
USA). All transfections were carried out using Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s protocol.
2.3. Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) analysis
Total RNA (including miRNA) was extracted using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions.
A M-MuLV reverse transcriptase (Promega, USA) was used to
create a cDNA library. Quantitative PCR was performed on an
Mx3000p (Stratagene, La Jolla, CA, USA) using GoTaq qPCR Master
Mix (Promega) according to the manufacturer’s instructions. The CT
values were determined through the Mx3000p software (version
4.10) using the ampliﬁcation-based threshold determination andadaptive baseline analysis options. b-Actin mRNA or U6 levels were
used for normalization. Primer sequences used in this study were
as follows:















Rabbit monoclonal anti-ADAM17 was purchased from Epito-
mics (Epitomics, USA). Mouse monoclonal anti-TNF-a was pur-
chased from ProteinTech (Proteintech, USA). Mouse polyclonal
anti-b-actin (CoWin Biotech, China) was used as an internal control
antibody. Proteins were extracted from cells with SDS lysis buffer
(BioRad, USA) and separated by SDS–PAGE. Subsequently, protein
samples were transferred to polyvinylidene diﬂuoride (PVDF, Mil-
lipore, USA) membranes, which were probed with primary anti-
bodies at 4 C overnight, followed by incubation with horseradish
peroxidase-conjugated secondary antibodies. Immunoreactivity
was detected by SuperSignal west pico Chemiluminescent Sub-
strate (Thermo Fisher Scientiﬁc, USA).
2.5. Dual-luciferase reporter gene assay
Luciferase reporter plasmids were generated by insertion of
target fragments into the multiple cloning site (XbaI and NdeI)
downstream of the Renilla luciferase reporter gene in the pGL-
3-control vector. The sequence from 2989–2995 (50-GCACUGA-30)
in the human ADAM17 mRNA (NM_003183.4) was designated
the miR-152 binding site. The 660-nt fragment of ADAM17 30UTR
(2659–3318, NM_003183.4) was generated using the following
primers: forward: 50-gctctagaTTTAGTTCTCAGCTCTTC-30; reverse:
50-ggaattccatatgCATGTATAGCCCTCACTGTA-30. 50 modiﬁed primers
carrying restriction sites for either XbaI or NdeI were used for
ampliﬁcation (sequence in lowercase). The miR-152 seed-site in
the 30UTR of ADAM17 was mutated to remove complete miR-152
binding site. Mutagenesis of the miR-152 binding site in the
ADAM17 30UTR was carried out using a previously reported
method [19] with the following primers: forward: 50-TTGTGAAGAC
TGGGAAGCAGATGCTGGTCA-30; reverse: 50-TGACCAGCATCTGCTTC
CCAGTCTTCACAA-30. All constructs were sequenced by Sangon
Biotech (Shanghai, China).
HUVEC were seeded 5  104 cells per well in 24-well plates and
transfected with 100 ng constructed luciferase reporters and 10 ng
pRL-TK as an internal control for transfection efﬁciency with
20 pmol miRNAmimics or negative control RNA. Fireﬂy and Renilla
luminescence was measured 48 h after transfection using the
Dual-Luciferase Reporter Assay System (Promega) according to
the manufacturer’s instructions. Measurements of luminescence
were performed on the luminometer (Glomax 20/20, Promega).
2.6. Enzyme-linked immunosorbent assay (ELISA)
The culture media of HUVEC were collected and centrifuged at
12,000 rpm for 10 min, and the clariﬁed supernatants were
Fig. 1. ADAM17 is a direct target gene of miR-152 in HUVEC. (A) Predicted miRNAs target sites in human ADAM17 30UTR with TargetScan 6.2 software. All the data analysis
and contributes scores are cited from the software. (B) Predicted duplex formation between miR-152 and the targeted ADAM17 30UTR, the predicted minimum free energy is
calculated by RNAhybrid 2.2 software. The target site of miR-152 in ADAM17 30UTR and miR-152 is conserved among mammalian species. (C) Insertion of ADAM17 30UTR
target sequence in the luciferase reporter vector led to the decreased luciferase activity in the presence of miR-152 in HUVEC 48 h after co-transfection. miR-152 is short for
miR-152 mimics, NC is short for negative control RNA. Values represent means of three independent experiments. (D) Real-time PCR analysis of miR-152 level in HUVEC
transfected with ADAM17 siRNA (siA17), miR-152 mimics and miR-152 inhibitors (miR-152 Inh). The expression level of miR-152 was normalized by using U6 as an internal
control and the expression level of ADAM17 mRNA was normalized by using b-actin as an internal control. Values represented means of three independent experiments. (E)
Real-time PCR was employed to analyze the expression level of ADAM17 in previously transfected HUVEC. The expression level of miR-152 was normalized by using U6 as an
internal control and the expression level of ADAM17 mRNA was normalized by using b-actin as an internal control. Values represented means of three independent
experiments. (F) Western blot analysis of protein extracts of HUVEC transfected with miR-152 versus a negative control RNA. MiR-152 overexpression decreases ADAM17
protein levels; b-actin was used as a loading control. ⁄P < 0.05 and ⁄⁄P < 0.01 are considered statistically signiﬁcant.
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supernatants by ELISA according to manufacturer’s instructions
(Sino Biological Inc., China).2.7. Hypoxic treatment
For hypoxic treatment, HUVEC were exposed to hypoxic condi-
tions in a hypoxic glove box (Coy Laboratory Products, USA). O2
level in the box was maintained at 1% and temperature at
37 C. Samples were collected for further analysis after 24 h
incubation.2.8. MTS assay
HUVEC proliferation was determined by CellTiter 96 AQueous
One Solution Assay (Promega). Equal numbers of 2  103 cells per
well were seeded in 96-well plates. After incubation under
different conditions for various periods of time, 20 ll 3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe nyl)-2-(4-sulf-
ophenyl)-2H-tetrazolium inner salt (MTS; Promega) was added
to each well. The plates were further cultured for 1 h. Absorbance
was measured at 490 nm with a microplate spectrophotometer
(Bio-Tek, USA).2.9. Wound-healing cell migration assay
HUVEC (1  105 cells per well) were grown to 80% conﬂuence in
a 24-well plate before wounding. The wound was made by scrap-
ing a conventional pipette tip across the monolayer. Cell migration
was induced by DMEM supplemented with 10% FBS. The image of
the wound was captured by microscopy (Olympus, Japan) immedi-
ately after wounding at 24 h intervals.Fig. 2. ADAM17 is a functional target gene of miR-152 in HUVEC. (A) TNF-a protein e
ADAM17 and TNF-a were analyzed by Western blot analyses; b-actin was used as a load
or miR-152 mimics for 48 h. Culture medium of cells were collected for measuring sT
experiments. (C) Effect of hypoxia on miR-145, miR-152 and miR-224 expression were an
ADAM17 mRNA was normalized by using b-actin as an internal control. (E) Western blot a
as a loading control. ⁄P < 0.05 and ⁄⁄P < 0.01 are considered statistically signiﬁcant.2.10. Transwell chamber migration assay
HUVEC (5  104 cells per well) were placed in serum-free
DMEM in 24-well Transwell inserts (8-lm pore size; Corning
Costar, USA), while the bottom chambers contained serum-supple-
mented medium. The migration of cells was allowed to proceed for
48 h at 37 C. Cells that migrated to the bottom of the insert were
ﬁxed with methanol at 20 C for 10 min and stained by 0.1% crys-
tal violet for 12 h and counted under the microscope (Olympus).
2.11. Statistics
All of the experiments were performed three times indepen-
dently. Statistical signiﬁcance of representative data was analyzed
by unpaired Student’s t test, P-values less than 0.05 (P < 0.05) were
considered signiﬁcant (⁄) and P-values less than 0.01 (P < 0.01)
were considered highly signiﬁcant (⁄⁄).
3. Results and discussion
3.1. ADAM17 is a direct target gene of miR-152 in HUVEC
Recent studies have shown that patients with AS show
increased expression of ADAM17 in plaques, indicating that
ADAM17 is an important target in AS pathogenesis. MiR-152 was
predicted to target ADAM17 in bioinformatics analysis using Tar-
getScan 6.2 software (Fig. 1A). MiR-152 and the predicted target
site of ADAM17 are conserved among different mammalian species
except for mouse (Fig. 1B). To test this prediction, we cloned the
wild-type and the mutated region of the miR-152 seed-site in
the 30UTR of ADAM17 into luciferase reporter plasmids. Dual lucif-
erase reporter gene assay showed that insertion of the ADAM17
30UTR target sequence in the luciferase reporter vector led to
decreased luciferase activity in the presence of miR-152 in HUVEC.xpression in ADAM17 siRNA or miR-152 mimics transfected HUVEC. The level of
ing control. (B) HUVEC were transfected with negative control RNA, ADAM17 siRNA
NF-a concentration using ELISA. Values represented means of three independent
alyzed by real-time PCR. U6 served as an internal control. (D) The expression level of
nalysis of protein extracts of HUVEC under normoxia and hypoxia; b-actin was used
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(Fig. 1C), indicating that ADAM17 is a direct target gene of
miR-152.
To verify the role of miR-152 in regulating ADAM17 expression,
we performed real-time PCR and Western blot assays in HUVEC.
Results showed that the mRNA and protein levels of ADAM17 were
decreased in cells transfected with either ADAM17 siRNA or an
miR-152 mimics compared with the levels detected in the control
groups (Fig. 1D–F). It is suggested that miR-152 could regulate the
gene expression of ADAM17 at both the mRNA and protein levels.
3.2. ADAM17 is a functional target gene of miR-152 in HUVEC
As ADAM17 is a well-known ectodomain sheddase, we then
tested whether miR-152 treatment could reduce TNF precursor
cleavage in endothelial cells. After ADAM17 siRNA and miR-152
transfection, results showed that miR-152 indeed reduced TNF pre-
cursor cleavage in HUVEC (Fig. 2A and B).
To evaluate the function of miR-152 targeting ADAM17 in phys-
iological situation, HUVECs were cultured under hypoxic condition.
The results showed that hypoxic treatment have reduced miR-152
expression and increased ADAM17 expression and TNF-a precur-
sor cleavage in HUVEC when compared to normoxia (Fig. 2C–E).
That is, the expression pattern of miR-152 and corresponding
target ADAM17 was changed oppositely in HUVEC under hypoxicFig. 3. MiR-152 inhibits HUVEC cell proliferation and migration. (A) MTS assay of HUVE
assay of HUVEC transfected with pCMV-myc (pCMV), pCMV-ADAM17-myc (pA17) and m
RNA, ADAM17 siRNA, miR-152 mimics, pCMV-myc and pCMV-ADAM17-myc. (D) Tran
ADAM17 siRNA, miR-152 mimics, pCMV-myc and pCMV-ADAM17-myc. Values represen
signiﬁcant.condition, which further conﬁrmed that ADAM17 was the func-
tional target of miR-152 in HUVEC.
3.3. MiR-152 inhibits HUVEC proliferation and migration
To investigate the function of miR-152 in HUVEC, MTS, wound-
healing and Transwell chamber migration assays were carried out.
Results showed that, compared with control cells, HUVEC transfec-
ted with the miR-152 mimics showed reduced proliferation levels
similar to those of ADAM17 siRNA-transfected cells (Fig. 3A), while
miR-152 inhibitors-transfected cells had the opposite effect. The
results of wound-healing and Transwell chamber migration assays
also showed that HUVEC transfected with the miR-152 mimics
showed a signiﬁcant decrease in migration ability (Fig. 3C and
D). HUVEC proliferation and migration could be partially rescued
by treatment with ADAM17 overexpression (Fig. 3A–C). Interest-
ingly, we found overexpression of miR-152 had no effect on
apoptosis of HUVEC in vitro (data not shown). Our results demon-
strated that miR-152 could affect the HUVEC cell fate which plays
important roles in the development of human atherosclerosis.
3.4. MiR-152 levels in clinical atherosclerosis patient serum samples
In atherosclerosis, microRNAs plays a crucial role in inﬂamma-
tion progress as previous reported and they could be detected inC transfected with negative control RNA, ADAM17 siRNA, miR-152 mimics. (B) MTS
iR-152 mimics. (C) Wound-healing assay of HUVEC transfected with negative control
swell chamber migration assay of HUVEC transfected with negative control RNA,
ted means of three independent experiments. ⁄P < 0.05 are considered statistically
Fig. 4. Serum miR-152 levels in clinically diagnosed atherosclerosis patients and normal individuals. The expression of miR-145 (A), miR-152 (B) and miR-224 (C) in the sera
of atherosclerosis patients and normal individuals was measured by qRT-PCR. The expression level of miRNAs was normalized by using miR-16 as an internal control.
⁄P < 0.05 are considered statistically signiﬁcant.
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ysis. To investigate the involvement of miRNAs in pharmacological
effects of atherosclerosis, we performed miRNA expression analy-
sis in clinical atherosclerosis patient serum samples. Analysis of
serummiR-152 revealed lower levels in AS patients compared with
those detected in normal individuals (Fig. 4B). However, there
were no signiﬁcant differences in the serum levels of other
predicted or reported miRNAs target ADAM17, such as miR-145
and miR-224 (Fig. 4A and C). This data suggested that miR-152
could be exert important function in AS; however, this requires
conﬁrmation by the analysis of greater numbers of serum samples
and investigation of the detailed mechanisms.
4. Discussion
It is reported previously that miR-145 targets ADAM17 in renal
cancer cells [13]. It is now known that miRNA targeting depend on
cell type and the nature of the environmental stimulus that trig-
gers targets dynamic changing [20]. Our results showed a more
perfect negative correlation of the expression pattern of miR-152
and corresponding target ADAM17 than that of other predicted
or reported miRNAs [21,22] in HUVEC under native state or
hypoxia condition. It is indicated that ADAM17 is the special func-
tional target of miR-152 in HUVEC.
MicroRNAs have been considered promising candidates for
diagnostic biomarkers because of the strong correlation between
microRNA expression patterns and disease status demonstrated
not only in animal models but also in patients. A lot of studies
suggest that serum microRNAs are reliable indicators of disease
status. We found that the levels of circulating miR-152 in AS
patient serum samples were much lower than that detected in
normal healthy serum samples, which indicated that miR-152
may be involved in the development of human atherosclerosis
and could be used as diagnostic biomarker.
In conclusion, we demonstrated for the ﬁrst time that miR-152
could reduce TNF precursor cleavage and inhibit cell proliferation
and migration by targeting ADAM17 in HUVEC. The expression
pattern of miR-152 and corresponding target ADAM17 was
opposite in HUVEC under hypoxic condition. The levels of circulat-
ing miR-152 in AS patient sera were much lower than those
detected in the sera of normal individuals Our results indicated
that miR-152 may be involved in the development of human ath-
erosclerosis and could be used as diagnostic biomarker or thera-
peutic target in atherosclerosis.
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